Literature DB >> 26224770

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.

Dakshina Chilukuri1, Owen McMaster2, Kimberly Bergman1, Philip Colangelo1, Kerry Snow2, Joseph G Toerner2.   

Abstract

Entities:  

Keywords:  antimycobacterial; in vitro; tuberculosis

Mesh：

Substances：

Year:  2015        PMID： 26224770     DOI： 10.1093/cid/civ460

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

1.  Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Authors:  Devyani Deshpande; Jotam G Pasipanodya; Stellah G Mpagama; Shashikant Srivastava; Paula Bendet; Thearith Koeuth; Pooi S Lee; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

2.  Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

3.  Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?

Authors:  Jean-Philippe Lanoix; Richard E Chaisson; Eric L Nuermberger
Journal:  Clin Infect Dis       Date:  2015-11-01       Impact factor: 9.079

4.  Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Authors:  Devyani Deshpande; Shashikant Srivastava; Paula Bendet; Katherine R Martin; Kayle N Cirrincione; Pooi S Lee; Jotam G Pasipanodya; Keertan Dheda; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

5.  Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

Authors:  Devyani Deshpande; Shashikant Srivastava; Moti Chapagain; Gesham Magombedze; Katherine R Martin; Kayle N Cirrincione; Pooi S Lee; Thearith Koeuth; Keertan Dheda; Tawanda Gumbo
Journal:  Sci Adv       Date:  2017-08-30       Impact factor: 14.136

6.  Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis.

Authors:  Shashikant Srivastava; Kayle N Cirrincione; Devyani Deshpande; Tawanda Gumbo
Journal:  Front Pharmacol       Date:  2021-01-19       Impact factor: 5.810

Review 7.  Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.

Authors:  Tawanda Gumbo; Mamodikoe K Makhene; James A Seddon
Journal:  Clin Infect Dis       Date:  2016-11-01       Impact factor: 9.079

8.  Comparison of Sputum-Culture Conversion for Mycobacterium bovis and M. tuberculosis.

Authors:  Colleen Scott; Joseph S Cavanaugh; Benjamin J Silk; Julia Ershova; Gerald H Mazurek; Philip A LoBue; Patrick K Moonan
Journal:  Emerg Infect Dis       Date:  2017-03       Impact factor: 6.883

9.  Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.

Authors:  Suresh Mallikaarjun; Moti L Chapagain; Tomohiro Sasaki; Norimitsu Hariguchi; Devyani Deshpande; Shashikant Srivastava; Alexander Berg; Kuniko Hirota; Yusuke Inoue; Makoto Matsumoto; Jeffrey Hafkin; Lawrence Geiter; Xiaofeng Wang; Tawanda Gumbo; Yongge Liu
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.